Frontlight ResearchEarly access
Fatty liver disease (MASLD/MASH) trials in Italy
22 of 32 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
- Where
- Bologna, Foggia, Messina, Milan, Modena, Naples, Novara, Rome, Rozzano, San Giovanni Rotondo, Turin
- Age
- 18 years and over
- People
- 232 worldwide
- Run by
- Akero Therapeutics Inc.
See details and how to join2023-505141-48-00 - Phase 3Taking peopleA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Where
- Bologna, Catania, Foggia, Messina, Milan, Modena, Novara, Roma, Rozzano, San Giovanni Rotondo, Torino
- Age
- 18 years to 80 years
- People
- 2,150 worldwide
- Run by
- Akero Therapeutics, Inc
See details and how to joinNCT06528314 - Phase 3Taking peopleLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- Where
- Bologna, Foggia, Milan, Modena, Palermo, Rome, Rozzano, San Giovanni Rotondo, Turin
- Age
- 18 years and over
- People
- 1,590 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00 - Phase 2Not yet taking people in ItalyStudy to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Where
- Bologna, Florence, Milan, Padova, Palermo, Rome
- Age
- 18 years to 75 years
- People
- 360 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07631637 · EU 2026-525916-33-00 - Phase 3Taking peopleA Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
- Where
- Bologna, Foggia, Messina, Milan, Modena, Naples, Novara, Roma, Rozzano, San Giovanni Rotondo, Torino
- Age
- 18 years to 80 years
- People
- 1,650 worldwide
- Run by
- Akero Therapeutics, Inc
See details and how to joinNCT06215716 - Phase 3Taking peopleLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
- Where
- Bologna, Foggia, Milan, Modena, Novara, Palermo, Rome, Rozzano, San Giovanni Rotondo, Turin, Verona
- Age
- 18 years and over
- People
- 1,800 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00 - Phase 3Taking peopleA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Where
- Bologna, Catania, Foggia, Messina, Milan, Modena, Novara, Rome, Rozzano, San Giovanni Rotondo, Turin
- Age
- 18 years and over
- People
- 205 worldwide
- Run by
- Akero Therapeutics Inc.
See details and how to join2024-512895-36-00 - Phase 3Taking peopleA Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- Where
- Bergamo, Foggia, Milan, Modena, Naples, Novara, Palermo, Rome, Rozzano, Turin
- Age
- 18 years to 80 years
- People
- 1,350 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- Where
- Bergamo, Foggia, Milan, Novara, Palermo, Rome, Rozzano, Turin
- Age
- 18 years to 75 years
- People
- 1,800 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00 - Phase 3Not yet taking people in ItalyA pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
- Where
- Bergamo, Bologna, Foggia, Milan, Padova, Rome, Rozzano
- Age
- 18 years and over
- People
- 382 worldwide
- Run by
- Glaxosmithkline Research & Development Limited
See details and how to join2026-525755-82-00 - Phase 3Not yet taking people in ItalyA study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
- Where
- Bergamo, Bologna, Foggia, Milan, Padova, Rome, Rozzano
- Age
- 18 years and over
- People
- 69 worldwide
- Run by
- Glaxosmithkline Research & Development Limited
See details and how to join2026-525757-37-00 - Phase 3Taking peopleA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Where
- Bergamo, Bologna, Florence, Milan, Naples, Padova, Palermo, Roma, Rome, Rozzano, Torino, Verona
- Age
- 18 years and over
- People
- 4,500 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00 - Phase 3Taking peopleA Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- Where
- Ancona, Bergamo, Bologna, Florence, Foggia, Milan, Padova, Rome, Rozzano, Turin
- Age
- 18 years to 75 years
- People
- 1,250 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07221188 · EU 2025-523674-16-00 - Phase 4Not yet taking people in ItalyFibrosis Lessens After Metabolic Surgery
- Where
- Milan, Roma
- Age
- 18 years to 75 years
- People
- 120 worldwide
- Run by
- The Cleveland Clinic
See details and how to joinNCT06374875 - No phaseNot yet taking people in ItalyUNMASK: Unveiling the Pathobiology of Metabolic Dysfunction-Associated Steatotic Liver Disease for the Discovery of Novel Therapeutics and Biomarkers
- Where
- Roma
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
See details and how to joinNCT07652151 - No phaseTaking peopleEVOO and Metabolic Liver Health in MASLD
- Where
- Castellana Grotte
- Age
- 18 years to 65 years
- People
- 60
- Run by
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
See details and how to joinNCT07412444 - No phaseTaking peopleEffects of Two Different Exercise Programs and Diet in Obese Subjects With NAFLD
- Where
- Castellana Grotte
- Age
- 18 years to 65 years
- People
- 90
- Run by
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
See details and how to joinNCT06186869 - No phaseTaking peopleEvaluation of Risk of hEpatocellular Carcinoma
- Where
- Milan
- Age
- 45 years to 75 years
- People
- 500
- Run by
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
See details and how to joinNCT06523179 - No phaseTaking peopleHuman Liver ORganoids as a Model to Study the Development of Non-Alcoholic SteatOhepatitis (NASH)
- Where
- Milan
- Age
- 18 years and over
- People
- 60
- Run by
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
See details and how to joinNCT06856252 - No phaseTaking peopleThe Liver BIoBank Lombardia of Fatty Liver
- Where
- Milan
- Age
- 40 years to 60 years
- People
- 2,500
- Run by
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
See details and how to joinNCT06566105 - No phaseNot yet taking people in ItalyKetogenic Diet in MASLD-related cACLD
- Where
- Palermo
- Age
- 18 years and over
- People
- 50
- Run by
- University of Palermo
See details and how to joinNCT06537466 - No phaseTaking peopleRole of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis
- Where
- Bologna
- Age
- 18 years and over
- People
- 42
- Run by
- University of Bologna
See details and how to joinNCT06308757